Hepatology international

Effectiveness of tirzepatide compared to SGLT2 inhibitors in fatty liver disease linked to metabolism problems

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated

Abstract

Tirzepatide may offer a promising treatment for metabolic dysfunction-associated steatotic liver disease (MASLD).

  • MASLD is linked to increased cardiometabolic and liver health risks.
  • Tirzepatide acts as a dual receptor agonist for GLP-1 and GIP.
  • Comparative data between tirzepatide and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in real-world settings is currently unavailable.

Simplified

Full Text

Full text is available at the source.
View Full Text ↗

Featured in

GLP-1 TherapiesGLP-1 TherapiesIssue #44
Tirzepatide cut all-cause mortality by more than half compared to semaglutide in a 47,000-patient study
↗

what lands in your inbox each week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the glp-1 therapies brief

issue #44
Tirzepatide cut all-cause mortality by more than half compared to semaglutide in a 47,000-patient study
today7 studies
issue #43
Semaglutide linked to 21% lower psychiatric hospitalization risk in bipolar disorder patients
1 week ago7 studies
issue #42
Tirzepatide users lost 14.7% of body weight vs. 10.8% with semaglutide — but Black and Hispanic patients were overrepresented in the lowest-response group
2 weeks ago8 studies
issue #41
New obesity drug survodutide cut weight by 13% vs 5.4% for placebo in 725 patients
3 weeks ago7 studies
issue #40
GLP-1 users had 3x higher risk of aspiration pneumonia after stroke surgery
4 weeks ago7 studies
issue #39
Semaglutide linked to reduced cigarette craving in 24 smokers
5 weeks ago7 studies
issue #38
Two-thirds of patients kept weight off after stopping GLP-1 drugs
6 weeks ago7 studies
issue #36
Tirzepatide beats semaglutide for weight loss: 8.2% vs 5.8% body weight reduction at 12 months
8 weeks ago7 studies
issue #35
Semaglutide linked to 2.5x higher risk of sudden vision loss
9 weeks ago7 studies
issue #34
Tirzepatide users had 18.4% weight loss vs 11.9% with semaglutide in head-to-head trial
10 weeks ago7 studies
explore the archive
See more issues from the glp-1 therapies brief